Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 7, 2010, Pages 689-691

  Tofovic, David S ^a   Bilan, Victor P ^a   Jackson, Edwin K ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

angiotensin II; dipeptidyl peptidase IV; kidney; renal vasoconstriction; sitagliptin; Type 2 diabetes

Indexed keywords

ANGIOTENSIN II; DIPEPTIDYL PEPTIDASE IV; GLUCOSE; HEMOGLOBIN A1C; SITAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE; VASOCONSTRICTOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HYPERTENSION; ISOLATED KIDNEY; KIDNEY BLOOD FLOW; MALE; MEAN ARTERIAL PRESSURE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN URINE LEVEL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; VASOCONSTRICTION; ANIMAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; GENETICS; KIDNEY; KIDNEY CIRCULATION; PROTEINURIA; VASCULARIZATION; WISTAR KYOTO RAT;

ANGIOTENSIN II; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HEMOGLOBIN A, GLYCOSYLATED; HYPERTENSION; KIDNEY; MALE; METABOLIC SYNDROME X; PROTEINURIA; PYRAZINES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RENAL CIRCULATION; TRIAZOLES; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 77953846542     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2010.05389.x     Document Type: Article

References (23)

1. Dubinion JH, Mi Z, Zhu C, Gao L, Jackson EK. Pancreatic polypeptide-fold peptide receptors and angiotensin II-induced renal vasoconstriction. Hypertension 2006 47: 545 551.
2. Dubinion JH, Mi Z, Jackson EK. Role of renal sympathetic nerves in regulating renovascular responses to angiotensin II in spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 2006 317: 1330 1336.
3. Berglund MM, Hipskind PA, Gehlert DR. Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. Exp. Biol. Med. 2003 228: 217 244.
4. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin. Sci. 2005 108: 277 292.
5. Michel MC, Beck-Sickinger A, Cox H et al. XVI International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 1998 50: 143 150.
6. Jackson EK, Mi Z. Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension. Hypertension 2008 51: 1637 1642.
7. 1-36-induced potentiation of angiotensin II-mediated renal vasoconstriction in spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 2007 323: 431 437.
8. Augustyns K, Van der Veken P, Senten K, Haemers A. The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases. Curr. Med. Chem. 2005 12: 971 998.
9. Bailey CJ. Drugs on the horizon for diabesity. Curr. Diab. Rep. 2005 5: 353 359.
10. Demuth HU, McIntosh CH, Pederson RA. Type 2 diabetes: Therapy with dipeptidyl peptidase IV inhibitors. Biochim. Biophys. Acta 2005 1751: 33 44.
11. Rafikova O, Salah EM, Tofovic SP. Renal and metabolic effects of tempol in obese ZSF1 rats: Distinct role for superoxide and hydrogen peroxide in diabetic renal injury. Metabolism 2008 57: 1434 1444.
12. 2-adrenoceptor interaction. J. Pharmacol. Exp. Ther. 2005 314: 1109 1116.
13. Bekersky I. Use of the isolated perfused kidney as a tool in drug disposition studies. Drug Metab. Rev. 1983 14: 931 960.
14. Mi Z, Jackson EK. Effects of α-and β-adrenoceptor blockade on purine secretion induced by sympathetic nerve stimulation in the rat kidney. J. Pharmacol. Exp. Ther. 1999 288: 295 301.
15. 2-Adrenoceptors potentiate angiotensin II-and vasopressin-induced renal vasoconstriction in spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 2003 305: 581 586.
16. Oellerich WF, Malik KU. Neuropeptide Y modulates the vascular response to periarterial nerve stimulation primarily by a postjunctional action in the isolated perfused rat kidney. J. Pharmacol. Exp. Ther. 1993 266: 1321 1329.
17. 2-adrenoceptors enhance angiotensin II-induced renal vasoconstriction. Role for NADPH oxidase and RhoA. Hypertension 2008 51: 719 726.
18. Grouzmann E, Livio F, Buclin T. Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: An increased risk of angioedema. Hypertension 2009 54: 468 470.
19. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 2009 54: 516 523.
20. Haefliger JA, Waeber B, Grouzmann E et al. Cellular localization, expression and regulation of neuropeptide Y in kidneys of hypertensive rats. Regul. Pept. 1999 82: 35 43.
21. 2-adrenoceptors and angiotensin II receptors in genetic hypertension. Hypertension 2001 38: 353 360.
22. Estacio RO. Renin-angiotensin-aldosterone system blockade in diabetes: Role of direct renin inhibitors. Postgrad. Med. 2009 121: 33 44.
23. Kirino Y, Sato Y, Kamimoto T, Kawazoe K, Minakuchi K, Nakahori Y. Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy. A streptozotocin-induced model using wild-type and DPP4-deficient rats. J. Endocrinol. 2009 200: 53 61.